Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...
After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...
US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...
Fintel on MSN2d
Cantor Fitzgerald Downgrades Supernus Pharmaceuticals (SUPN)Fintel reports that on February 19, 2025, Cantor Fitzgerald downgraded their outlook for Supernus Pharmaceuticals ...
The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, ...
The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...
Investigational drug SPN-820, which activates the mTORC1 pathway, failed to significantly reduce depressive symptoms compared ...
Supernus Pharmaceutical’s stock declined following the release of disappointing Phase IIb trial results for SPN-820, an ...
Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...
3d
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
Supernus Pharmaceuticals (NASDAQ:SUPN) stock drops as depression candidate SPN-820 misses main goals in Phase 2b trial. Read more here.
Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback